Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
Merus N.V. - Common Shares (MRUS)
Last merus n.v. - common shares earnings: 8/19 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/mrus
Company Research
Source: GlobeNewswire
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research (AACR) Annual Meeting 2024. “Exemplary of our approach to developing multispecific antibodies, Zeno was selected utilizing unbiased assays to allow biology to teach us which is the best potential Biclonics®. Thereafter, we continue to learn more both preclinically and mechanistically, to identify where the molecule holds potential,” said Cecile Geuijen, Chief Scientific Officer of Merus. “In this study, we examined the efficacy of Zeno in preclinical models expressing high NRG1 levels and found evidence of anti-tumor activity in multiple t
Show less
Read more
Impact Snapshot
Event Time:
MRUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRUS alerts
High impacting Merus N.V. - Common Shares news events
Weekly update
A roundup of the hottest topics
MRUS
News
- Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual MeetingGlobeNewswire
- Merus (NASDAQ: MRUS) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.MarketBeat
- Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Merus (NASDAQ: MRUS) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $69.00 price target on the stock.MarketBeat
MRUS
Earnings
- 11/2/23 - Beat
MRUS
Sec Filings
- 4/11/24 - Form DEFA14A
- 4/10/24 - Form DEF
- 3/29/24 - Form PRE
- MRUS's page on the SEC website